Prolor Biotech

The most common form of diabetes, accounting for roughly 90% to 95% of diagnosed diabetes cases worldwide, is Type 2 diabetes—a condition where the body either does not produce enough insulin or its cells ignore the insulin. Insulin is required to transport glucose from the blood into the cells. When the body does not perform this function, glucose accumulates in the blood instead of entering the cells, resulting in hyperglycemia. This can starve the body’s cells for energy, and over time, injure the eyes, kidneys, nerves, or heart.

If present at all, symptoms of Type 2 diabetes may include fatigue, blurred vision, frequent or slow-healing infections, erectile dysfunction, or increased thirst, urination, and appetite. Long-term complications of Type 2 diabetes may include diabetic retinopathy (eye disease), diabetic nephropathy (kidney disease), diabetic neuropathy (nerve damage), damage to blood vessels and circulation, high cholesterol, high blood pressure, atherosclerosis, and coronary artery disease. A diabetic coma could occur as an emergency complication. Due in large part to an increase in obesity, the prevalence of Type 2 diabetes has tripled in the last 30 years. According to the National Diabetes Information Clearinghouse, diabetes now afflicts more than 20.8 million U.S. citizens, and in 2002, was estimated to cost the U.S. $132 billion. Globally, in 2002, spending on oral diabetes drugs and injected insulin alone was $12.5 billion. The World Health Organization (WHO) estimates the global prevalence of diabetes at more than 180 million people, a number likely to more than double by 2030.

PROLOR's GLP-1 / Glucagon dual receptor agonist is a long-acting version of a therapeutic peptide that occurs naturally in the human body, and is developed for a once a week injection profile. The unique feature of the product is its expected superior fat loss and weight reduction profile, compared to GLP-1 therapies. Since the GLP-1 / Glucagon dual receptor agonist compound has specific activity in the brain and must cross the blood-brain barrier, the compound was developed using our RevPEG technology.